Want to see PALI full AI Analyst Report?
PALI Stock Chart & Stats
$2.03
$0.08(4.10%)
At close: 4:00 PM EDT
$2.03
$0.08(4.10%)
Day’s Range― - ―
52-Week Range$0.53 - $2.86
Previous CloseN/A
Volume1.43M
Average Volume (3M)4.07M
Market Cap
$341.57M
Enterprise Value$316.62
Total Cash (Recent Filing)$125.17M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Nov 16, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding174,270,550
10 Day Avg. Volume2,909,743
30 Day Avg. Volume4,071,253
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside244.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthLow leverage and a sizable equity base give Palisade structural financial flexibility uncommon for pre-revenue biotechs. This supports continued R&D spending and reduces near-term refinancing risk, lengthening the runway for clinical programs and strategic optionality over months.
FDA Clearance To Start UC StudyRegulatory clearance to start an ulcerative colitis study is a structural milestone: it enables formal clinical progress toward pivotal evidence, de-risks the program's regulatory path, and can materially improve partner/investor engagement and enrollment timelines over the next several months.
Shareholder Support And Financing FlexibilityShareholder approval for charter amendments and equity plans signals governance support and provides deliberate capital-raising tools. This increases the company's ability to fund development, grant incentives, or pursue deals without immediate ad-hoc approvals, improving strategic flexibility.
Bears Say
Pre-revenue With Widening LossesThe company remains essentially pre-revenue while operating losses roughly doubled year-over-year. Persistent negative profitability and rising spending compress returns and increase reliance on external capital, pressuring the business if clinical progress or funding access slows.
Negative Free Cash Flow And Rising BurnSustained negative operating and free cash flow, with a material step-up in burn, creates structural funding risk. If the trend persists, management will likely need to raise capital within months, which can force dilution or constrain program execution and strategic choices.
Heightened Dilution Risk From Charter ChangesExpanded authorized shares and approved equity plans increase the probability of future dilution—a structural downside given the company's cash burn and pre-revenue status. Capital raises or equity-based compensation over the next 2-6 months may dilute existing holders and affect per-share economics.
Palisade Bio News
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.53 and its highest was $2.85 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $341.57M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s upcoming earnings report date is Nov 16, 2026 which is in 94 days.
How were Palisade Bio’s earnings last quarter?
Palisade Bio released its earnings results on Aug 10, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.052 by $0.002.
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -0.06.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 174,270,550 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Palisade Bio reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.052. Following the earnings report the stock price went up 1.905%.
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (244.83% Upside)
$7.00 (244.83% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $249.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1809.63%
Trailing 12-Months
Company Description
Palisade Bio
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$7.00
▲(244.83% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
2.24% Insiders
4.60% Mutual Funds
12.37% Other Institutional Investors
74.91% Public Companies and
Individual Investors